1<!DOCTYPE html>
2
3Anonymous
4/bestp
5/bestp/domrep.nsf
6552A4532C2817ABD85257656003514BB
8
9
10
11
12
13
140
15
16
17/bestp/domrep.nsf/products/db-thought-leader-relationship-management-best-practices?opendocument
18
19opendocument
203.85.92.139
21
22
23www.best-in-class.com
24/bestp/domrep.nsf
25DB




Products & Services Medical Affairs Thought Leader Services

Thought Leader Relationship Management Best Practices

ID: 5056


Features:

12 Info Graphics

14 Data Graphics

79 Metrics


Pages/Slides: 42


Published: Pre-2014


Delivery Format: Online PDF Document


 

License Options:
close

Single User: Authorizes use by the person who places the order or for whom the order was placed.

Sitewide: Authorizes use of the report for a geographic site. All people at site can view the report for a year and copies can be printed.

Corporate: Authorizes use for the entire company for a year and copies can be printed. No limitations for usage inside the company.




Buy Now

 


  • STUDY OVERVIEW
  • BENCHMARK CLASS
  • STUDY SNAPSHOT
  • SPECIAL OFFER
Key Opinion Leaders (KOLs) have proven to be among of the most effective and critical means of building product awareness in the medical and scientific communities. Indeed, KOL relationship management itself has emerged as a necessary and vital part of brand success.


This updated Best Practices, LLC research from 2012 examines how leading pharmaceutical companies approach KOL management.

This study identifies the critical success factors associated with KOL management excellence. Pharma executives can use this benchmarking research to learn best practices in KOL management and discover how they can maximize KOL relationships to benefit their own products and therapies.


Industries Profiled:
Medical Device; Medical; Pharmaceutical; Biotech; Consulting; Consumer Products; Diagnostic; Marketing; Health Care


Companies Profiled:
Becton Dickinson; ArjoHuntleigh; GlaxoSmithKline ; Medinnovation; Dendreon Corporation; Scientific Advantage; Abbott Laboratories; Galen Ltd; Shire; Stallergenes; Smith & Nephew; Santarus; Inc.; Bayer Healthcare; The Arcas Group; Teva Pharmaceutical Industries Ltd; Pierre Fabre Medicament; MSD; Janssen; Medtronic; Takeda Pharmaceuticals; Onyx Pharmaceuticals; Boston Scientific; Kadmon Pharmaceuticals; Novo Nordisk; Boehringer Ingelheim; Hospira; Pfizer; Eli Lilly


Study Snapshot

This research involved an online survey of nearly 36 respondents representing 30 different biopharmaceutical companies. More than 80 percent of participants were from Medical Affairs or Clinical Affairs departments.

Key topics include:
  • KOL Relationship Management Structure and Staffing
  • KOL Management Approaches and Tactics
  • Evaluating KOL Relationships and Value

If you purchase Best Practice Database document(s), you will have 30 days from the date of purchase to apply some or all of the cost of the document(s) toward the cost of a Full Access Individual, Pharma, Group or University Membership. Write us at DatabaseTeam@bestpracticesllc.com or call David Guinn at 919-767-9179 if you have any questions.